IL278978B2 - Preparations and methods for treating psoriasis - Google Patents
Preparations and methods for treating psoriasisInfo
- Publication number
- IL278978B2 IL278978B2 IL278978A IL27897820A IL278978B2 IL 278978 B2 IL278978 B2 IL 278978B2 IL 278978 A IL278978 A IL 278978A IL 27897820 A IL27897820 A IL 27897820A IL 278978 B2 IL278978 B2 IL 278978B2
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- seq
- psoriasis
- subject
- fragment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677590P | 2018-05-29 | 2018-05-29 | |
| PCT/US2019/034423 WO2019232070A1 (en) | 2018-05-29 | 2019-05-29 | Compositions and methods for treatment of psoriasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL278978A IL278978A (en) | 2021-01-31 |
| IL278978B1 IL278978B1 (en) | 2025-09-01 |
| IL278978B2 true IL278978B2 (en) | 2026-01-01 |
Family
ID=68697289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL278978A IL278978B2 (en) | 2018-05-29 | 2019-05-29 | Preparations and methods for treating psoriasis |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12016921B2 (https=) |
| EP (1) | EP3801590A4 (https=) |
| JP (1) | JP7357646B2 (https=) |
| KR (1) | KR102940600B1 (https=) |
| CN (1) | CN112689512B (https=) |
| AU (1) | AU2019279883B2 (https=) |
| CA (1) | CA3101767A1 (https=) |
| IL (1) | IL278978B2 (https=) |
| WO (1) | WO2019232070A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
| US11690912B2 (en) * | 2018-05-29 | 2023-07-04 | Abcentra, Llc | Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody |
| EP4058042A4 (en) * | 2019-11-12 | 2023-12-27 | Abcentra, LLC | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
| WO2024194686A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| WO2025151468A1 (en) * | 2024-01-08 | 2025-07-17 | Abcentra, Llc | Methods of identifying a subject for treatment with antibodies against oxidized low density lipoprotein using pericoronary fat attenuation index |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0103754L (sv) | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
| WO2008104194A1 (en) | 2007-02-28 | 2008-09-04 | Bioinvent International Ab | Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques |
| US8557767B2 (en) * | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| UA100255C2 (uk) * | 2007-12-28 | 2012-12-10 | Біоінвент Інтернешенл Аб | Фармацевтична композиція |
| EP2274333A4 (en) * | 2008-03-18 | 2011-06-15 | Abbott Lab | PROCESS FOR TREATING PSORIASIS |
| KR20120111724A (ko) | 2009-08-28 | 2012-10-10 | 제넨테크, 인크. | 항-산화된 ldl 항체를 이용한 치료 방법 |
| MX2013003920A (es) * | 2010-10-06 | 2013-06-03 | Abbvie Inc | Metodos para el tratamiento de la psoriasis. |
| WO2016024254A1 (en) | 2014-08-15 | 2016-02-18 | Fundació Hospital Universitari Vall D’Hebron-Institut De Recerca | Therapy selection for psoriasis and psoriatic arthritis |
| US11690912B2 (en) | 2018-05-29 | 2023-07-04 | Abcentra, Llc | Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody |
-
2019
- 2019-05-29 US US17/058,537 patent/US12016921B2/en active Active
- 2019-05-29 WO PCT/US2019/034423 patent/WO2019232070A1/en not_active Ceased
- 2019-05-29 JP JP2020567123A patent/JP7357646B2/ja active Active
- 2019-05-29 AU AU2019279883A patent/AU2019279883B2/en active Active
- 2019-05-29 CA CA3101767A patent/CA3101767A1/en active Pending
- 2019-05-29 EP EP19811281.5A patent/EP3801590A4/en active Pending
- 2019-05-29 KR KR1020207037596A patent/KR102940600B1/ko active Active
- 2019-05-29 IL IL278978A patent/IL278978B2/en unknown
- 2019-05-29 CN CN201980050534.6A patent/CN112689512B/zh active Active
-
2024
- 2024-06-21 US US18/750,581 patent/US20250161440A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3801590A1 (en) | 2021-04-14 |
| EP3801590A4 (en) | 2022-03-16 |
| WO2019232070A1 (en) | 2019-12-05 |
| US20250161440A1 (en) | 2025-05-22 |
| CN112689512A (zh) | 2021-04-20 |
| JP7357646B2 (ja) | 2023-10-06 |
| IL278978A (en) | 2021-01-31 |
| KR20210044742A (ko) | 2021-04-23 |
| US12016921B2 (en) | 2024-06-25 |
| US20210205448A1 (en) | 2021-07-08 |
| AU2019279883A1 (en) | 2021-01-21 |
| KR102940600B1 (ko) | 2026-03-18 |
| CN112689512B (zh) | 2025-09-05 |
| CA3101767A1 (en) | 2019-12-05 |
| AU2019279883B2 (en) | 2025-05-22 |
| JP2021530438A (ja) | 2021-11-11 |
| IL278978B1 (en) | 2025-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250161440A1 (en) | Compositions and methods for treatment of psoriasis | |
| US11214621B2 (en) | Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist | |
| CN105517570B (zh) | 通过施用il-4r拮抗剂治疗鼻息肉症的方法 | |
| US12458694B2 (en) | Methods for treatment of accelerated atherosclerosis and rheumatoid arthritis with an anti-Apo B100 antibody | |
| US20240059783A1 (en) | Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders | |
| KR20240155388A (ko) | 두부 판상 건선을 가진 대상체의 치료 방법 | |
| US20220177568A1 (en) | Treatment of skin lesions and pruritus in prurigo nodularis patients | |
| US20250011417A1 (en) | Methods for the treatment of thyroid eye disease | |
| HK40052952A (en) | Compositions and methods for treatment of psoriasis | |
| EP3952993B1 (en) | Method of treating fumaric acid ester-resistant plaque psoriasis | |
| TW202511290A (zh) | 一種重組抗IL-23p19抗體治療中重度銀屑病的方法 | |
| WO2024155810A1 (en) | Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy | |
| TW202521154A (zh) | 既往接受生物製劑治療斑塊狀銀屑病的受試者轉用抗IL23p19抗體治療斑塊狀銀屑病的方法 | |
| CN121889429A (zh) | 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体 | |
| KR20260057215A (ko) | 결절성 양진 환자에서 피부 병변 및 소양증의 치료 |